标题
Targeted therapy in gastroesophageal cancers: past, present and future: Figure 1.
作者
关键词
-
出版物
Gastroenterology Report
Volume -, Issue -, Pages gov052
出版商
Oxford University Press (OUP)
发表日期
2015-10-29
DOI
10.1093/gastro/gov052
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial.
- (2017) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression
- (2015) M Zhu et al. BRITISH JOURNAL OF CANCER
- Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: A retrospective study
- (2015) Émilie Soularue et al. BULLETIN DU CANCER
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
- (2015) Sylvie Lorenzen et al. EUROPEAN JOURNAL OF CANCER
- Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer
- (2015) Min-Hee Ryu et al. EUROPEAN JOURNAL OF CANCER
- High-Dose Chemotherapy for Recurrent Ovarian Germ Cell Tumors
- (2015) Natraj Reddy Ammakkanavar et al. JOURNAL OF CLINICAL ONCOLOGY
- Primum Non Nocere: Active Surveillance for Clinical Stage I Testicular Cancer
- (2015) David J. Vaughn JOURNAL OF CLINICAL ONCOLOGY
- A phase II trial of 5-weekly S-1 plus cisplatin (CDDP) combination with trastuzumab (Tmab) for HER2-positive advanced gastric or esophagogastric junction (EGJ) cancer: WJOG7212G (T-SPACE) study.
- (2015) Yuji Miura et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter phase II study of trastuzumab with S-1 alone in elderly patients with HER-2 positive advanced gastric cancer (JACCRO GC-06).
- (2015) Toshiki Masuishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Hospital Volume, Complications, and Cost of Cancer Surgery in the Elderly
- (2015) Hari Nathan et al. JOURNAL OF CLINICAL ONCOLOGY
- Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012.
- (2015) Kei Muro et al. JOURNAL OF CLINICAL ONCOLOGY
- Update on Metastatic Gastric and Esophageal Cancers
- (2015) Manish A. Shah JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab refractory esophagogastric (EG) cancer.
- (2015) Yelena Yuriy Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer.
- (2015) Eunice Lee Kwak et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti–Vascular Endothelial Growth Factor Therapy in Breast Cancer: Game Over?
- (2015) George W. Sledge JOURNAL OF CLINICAL ONCOLOGY
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimizing Treatment of HER2-Positive Breast Cancer
- (2015) William J. Gradishar Journal of the National Comprehensive Cancer Network
- Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Jin Li et al. LANCET ONCOLOGY
- S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer
- (2015) Feng Du et al. MEDICINE
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051)†
- (2014) A. C. Lockhart et al. ANNALS OF ONCOLOGY
- A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer
- (2014) Y-K Kang et al. BRITISH JOURNAL OF CANCER
- HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma
- (2014) Y J Liu et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)
- (2014) Lin Shen et al. Gastric Cancer
- Preoperative Chemoradiation Therapy in Combination With Panitumumab for Patients With Resectable Esophageal Cancer: The PACT Study
- (2014) Sil Kordes et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Cardiac Metastasis in Merkel Cell Carcinoma
- (2014) Clare F. Suttie et al. JOURNAL OF CLINICAL ONCOLOGY
- Body Mass Index and Risk of Second Obesity-Associated Cancers After Colorectal Cancer: A Pooled Analysis of Prospective Cohort Studies
- (2014) Todd M. Gibson et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Controlled Trial of a Telephone-Based Peer-Support Program for Women Carrying aBRCA1orBRCA2Mutation: Impact on Psychological Distress
- (2014) Victoria M. White et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
- (2014) Timothy Iveson et al. LANCET ONCOLOGY
- Gefitinib for oesophageal cancer: a cog in need of a wheel?
- (2014) Hugo E R Ford LANCET ONCOLOGY
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- MET inhibitors start on road to recovery
- (2014) Ken Garber NATURE REVIEWS DRUG DISCOVERY
- Risk of gastrointestinal perforation in cancer patients treated with aflibercept: a systematic review and meta-analysis
- (2014) Wei-Xiang Qi et al. TUMOR BIOLOGY
- Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab
- (2013) W. J. Gradishar ANNALS OF ONCOLOGY
- Squamous Dysplasia--The Precursor Lesion for Esophageal Squamous Cell Carcinoma
- (2013) P. R. Taylor et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Aflibercept
- (2013) K. K. Ciombor et al. CLINICAL CANCER RESEARCH
- Afatinib: First Global Approval
- (2013) Rosselle T. Dungo et al. DRUGS
- Results of docetaxel plus oxaliplatin (DOCOX)±cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: Results of a randomised Phase 2 study
- (2013) Donald Richards et al. EUROPEAN JOURNAL OF CANCER
- Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials
- (2013) A.F.C. Okines et al. EUROPEAN JOURNAL OF CANCER
- Targeted inhibition of VEGF receptor 2: an update on ramucirumab
- (2013) Jeffrey Melson Clarke et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer
- (2013) Yasuhide Yamada et al. Gastric Cancer
- Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study
- (2013) M. Martin-Richard et al. INVESTIGATIONAL NEW DRUGS
- Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways
- (2013) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial
- (2013) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Targeted therapy and chemoradiotherapy in oesophageal cancer
- (2013) Bryan H Burmeister et al. LANCET ONCOLOGY
- Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial
- (2013) Thomas Crosby et al. LANCET ONCOLOGY
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- (2013) Tom Waddell et al. LANCET ONCOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
- (2013) Hugo E R Ford et al. LANCET ONCOLOGY
- Preoperative Cetuximab, Irinotecan, Cisplatin, and Radiation Therapy for Patients With Locally Advanced Esophageal Cancer
- (2013) M. S. Lee et al. ONCOLOGIST
- S-1-Based Chemotherapy versus Capecitabine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Carcinoma: A Meta-Analysis
- (2013) Ming-ming He et al. PLoS One
- MET: A Critical Player in Tumorigenesis and Therapeutic Target
- (2013) C. R. Graveel et al. Cold Spring Harbor Perspectives in Biology
- Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report
- (2012) A. F. C. Okines et al. ANNALS OF ONCOLOGY
- Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis
- (2012) Y. Y. Janjigian et al. ANNALS OF ONCOLOGY
- Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum
- (2012) J H Yi et al. BRITISH JOURNAL OF CANCER
- Targeting the HGF/Met signaling pathway in cancer therapy
- (2012) Fabiola Cecchi et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Is Gastric Cancer Again Rising?
- (2012) Amy L. Zhu et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
- (2012) Jung Hun Kang et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Plus Paclitaxel in Patients with Advanced Esophageal Cancer: A Phase II Study from the Hoosier Oncology Groupe
- (2012) Jordan M. Schmitt et al. Journal of Thoracic Oncology
- Cetuximab Plus Cisplatin, Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced, Unresectable Esophageal Cancer: A Phase-II Study of The SWOG (S0414)
- (2012) Michael B. Tomblyn et al. Journal of Thoracic Oncology
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification
- (2012) W. Okamoto et al. MOLECULAR CANCER THERAPEUTICS
- Comparative Genomic Analysis of Esophageal Adenocarcinoma and Squamous Cell Carcinoma
- (2012) Nishant Agrawal et al. Cancer Discovery
- A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma
- (2011) J. A. Chan et al. ANNALS OF ONCOLOGY
- Evaluation of HER2 Protein Expression in Gastric Carcinomas: Comparative Analysis of 1414 Cases of Whole-Tissue Sections and 595 Cases of Tissue Microarrays
- (2011) Kab Choong Kim et al. ANNALS OF SURGICAL ONCOLOGY
- Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial
- (2011) T Shiroiwa et al. BRITISH JOURNAL OF CANCER
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- MET Expression and Amplification in Patients with Localized Gastric Cancer
- (2011) Y. Y. Janjigian et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models
- (2011) Y. Yamashita-Kashima et al. CLINICAL CANCER RESEARCH
- An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer
- (2011) M. Moehler et al. EUROPEAN JOURNAL OF CANCER
- T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract
- (2011) Binfeng Lu et al. IMMUNOLOGIC RESEARCH
- MET Signaling Pathway: A Rational Target for Cancer Therapy
- (2011) Leonard J. Appleman JOURNAL OF CLINICAL ONCOLOGY
- Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy
- (2011) Christiane Maria Rosina Thallinger et al. JOURNAL OF CLINICAL ONCOLOGY
- METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
- (2011) Jochen K. Lennerz et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2011) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-EGFR Monoclonal Antibodies for Treatment of Colorectal Cancers: Development of Cetuximab and Panitumumab
- (2011) Benoit You et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the human EGFR family in esophagogastric cancer
- (2011) Alicia Okines et al. Nature Reviews Clinical Oncology
- Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study
- (2010) M. Moehler et al. ANNALS OF ONCOLOGY
- Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2010) F Lordick et al. BRITISH JOURNAL OF CANCER
- The Clinicopathological Significance of Tissue Levels of Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor in Gastric Cancer
- (2010) Seong-Eun Kim et al. Gut and Liver
- Alcohol drinking and esophageal squamous cell carcinoma with focus on light-drinkers and never-smokers: A systematic review and meta-analysis
- (2010) Farhad Islami et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer
- (2010) Chul Kim et al. INVESTIGATIONAL NEW DRUGS
- Phase II study of sunitinib as second-line treatment for advanced gastric cancer
- (2010) Yung-Jue Bang et al. INVESTIGATIONAL NEW DRUGS
- Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial
- (2010) Alicia F.C. Okines et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203
- (2010) Weijing Sun et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab as Second-Line Therapy in Patients with Metastatic Esophageal Adenocarcinoma: A Phase II Southwest Oncology Group Study (S0415)
- (2010) Philip J. Gold et al. Journal of Thoracic Oncology
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- S-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: a meta-analysis
- (2010) Jiahao Huang et al. MEDICAL ONCOLOGY
- Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition
- (2010) Simona Corso et al. Molecular Cancer
- HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
- (2010) Josef Rüschoff et al. VIRCHOWS ARCHIV
- Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer
- (2009) S-W Han et al. BRITISH JOURNAL OF CANCER
- A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
- (2009) Chul Kim et al. INVESTIGATIONAL NEW DRUGS
- Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
- (2009) Axel Grothey et al. Nature Reviews Clinical Oncology
- EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number
- (2008) M A Kim et al. HISTOPATHOLOGY
- Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
- (2008) Salah-Eddin Al-Batran et al. JOURNAL OF CLINICAL ONCOLOGY
- Signaling networks assembled by oncogenic EGFR and c-Met
- (2008) A. Guo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started